Target intelligence / Profile preview

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)

Target
PFKFB3
Molecular classification
Enzyme (dual kinase and phosphatase activity), Transferase (for kinase domain), Hydrolase (for phosphatase domain)
01

Overview

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) is a bifunctional enzyme responsible for both the synthesis and degradation of fructose-2,6-bisphosphate, a key regulator of glucose metabolism in mammals. It participates in both glycolysis (via its kinase activity) and gluconeogenesis (via its bisphosphatase activity), and is highly inducible, especially in rapidly proliferating cells like tumor cells. The enzyme has a much higher kinase-to-phosphatase activity ratio than other family members, strongly favoring the generation of fructose-2,6-bisphosphate and thus promoting glycolytic flux. PFKFB3 activity is also essential for cell cycle progression and cell survival, linking metabolic control to cell proliferation and apoptosis prevention. Overexpression of PFKFB3 is frequently observed in cancer, where it supports the metabolic demands of tumor growth and is regulated by factors such as hypoxia-inducible factor-1 alpha (HIF-1α). As such, PFKFB3 is under investigation as a therapeutic target in oncology and metabolic disease.

Other names
PFK-2/FBPase-2 3inducible PFK-2PFKFB36PF-2-K/F-2,6-P2asePFK-2/FBPase-2 isozyme 3
02

Mechanism of action

Inhibition of PFKFB3 lowers fructose-2,6-bisphosphate levels, reducing glycolytic flux, arresting the cell cycle, and promoting apoptosis, particularly in cancer cells

03

Biological functions

Regulation of glycolysisRegulation of gluconeogenesisCell cycle progressionPrevention of apoptosis/cell survivalRegulation of glucose metabolism
04

Disease associations

Cancer (solid tumors, leukemias; tumor proliferation)Metabolic disorders (glucose homeostasis, diabetes)Other (potential role in cardiovascular disease via metabolic regulation, suggested but not deeply detailed in the available sources)
05

Safety considerations

Targeting PFKFB3 may impact general glucose metabolism in normal tissues and organs, raising concerns about hypoglycemia, metabolic disturbance, or impaired cell proliferation in non-cancerous tissue (risks inferred from metabolic centrality, not explicitly detailed in cited sources)
06

Interacting drugs

3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one)

1 more in the full profile.

07

Biomarkers

Overexpression of PFKFB3 can serve as a biomarker for tumor proliferation/aggressivenessIncreased fructose-2,6-bisphosphate or mRNA/protein levels in tissue samples

Beyond the preview

Go deeper on 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call